Clinical trial
Stereotactic Intracerebral Injection of Allogenic Induced Pluripotent Stem Cell-derived Dopamine Progenitor Cells in Patients With Parkinson's Disease
NCT07212088 is registered in ClinicalTrials.gov with iCamuno Biotherapeutics Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Stereotactic Intracerebral Injection of Allogenic Induced Pluripotent Stem Cell-derived Dopamine Progenitor Cells in Patients With Parkinson's Disease
- Lead sponsor
- iCamuno Biotherapeutics Ltd.
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- February 28, 2026
- Completion date
- June 15, 2028
- Enrollment
- 12 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.